Prolonged Therapy With Erythropoietin is Safe and Prevents Deterioration of Left Ventricular Systolic Function in a Porcine Model of Myocardial Infarction

This publication has 27 references indexed in Scilit:

• Erythropoietin protects myocardin-expressing cardiac stem cells against cytotoxicity of tumor necrosis factor-α
  Experimental Cell Research, 2009
• Erythropoietin administration after myocardial infarction in mice attenuates ischemic cardiomyopathy associated with enhanced homing of bone marrow‐derived progenitor cells via the CXCR‐4/SDF‐1 axis
  The FASEB Journal, 2008
• Erythropoietin in heart and vessels: focus on transcription and signalling pathways
  Journal of Thrombosis and Thrombolysis, 2008
• Erythropoietin improves cardiac function through endothelial progenitor cell and vascular endothelial growth factor mediated neovascularization
  European Heart Journal, 2007
• Delayed erythropoietin therapy reduces post-MI cardiac remodeling only at a dose that mobilizes endothelial progenitor cells
  American Journal of Physiology-Heart and Circulatory Physiology, 2007
• Erythropoietin protects cardiomyocytes from apoptosis via up-regulation of endothelial nitric oxide synthase
  Cardiovascular Research, 2006
• Erythropoietin prevents the acute myocardial inflammatory response induced by ischemia/reperfusion via induction of AP-1
  Cardiovascular Research, 2005
• Isolation and Expansion of Adult Cardiac Stem Cells From Human and Murine Heart
  Circulation Research, 2004
• Erythropoietin improves left ventricular function and coronary flow in an experimental model of ischemia‐reperfusion injury
  European Journal of Heart Failure, 2004
• Erythropoietin is a potent physiologic stimulus for endothelial progenitor cell mobilization
  Blood, 2003